Tag
Large-scale trials in Kenya and Mozambique demonstrate that ivermectin mass drug administration significantly reduces malaria incidence by 26% and lowers community scabies prevalence, providing both direct protection and indirect herd-like
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide)
A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.
Recent cluster-randomized trials in Kenya and Burkina Faso provide mixed but informative evidence on the efficacy and safety of mass ivermectin administration for malaria control, highlighting both its potential and limitations.
